Back to Authors

Bowers, Cyril Y.

Mayo Clinic

Tulane University

Citations 25

Determinants of Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Premenopausal Women Studied under a Selective Estradiol Clamp
Erickson, Dana , Keenan, Daniel M., Farhy, Leon S. , Mielke, Kristi L., Bowers, Cyril Y., Veldhuis, Johannes D.

The Journal of Clinical Endocrinology & Metabolism | March 9, 2005 | Volume: 90 | Issue: 3 | Pages: 1741-1751

10.1210/jc.2004-1621 Get It

Endocrine Control of Body Composition in Infancy, Childhood, and Puberty
Veldhuis, Johannes D. , Roemmich, James N. , Richmond, Erick , Rogol, Alan D. , Lovejoy, Jennifer C., Sheffield‐Moore, Melinda , Mauras, Nelly , Bowers, Cyril Y.

Endocrine Reviews | February 2, 2005 | Volume: 26 | Issue: 1 | Pages: 114-146

10.1210/er.2003-0038 Get It

Dual Secretagogue Drive of Burst-Like Growth Hormone Secretion in Postmenopausal Compared with Premenopausal Women Studied under an Experimental Estradiol Clamp
Erickson, Dana , Keenan, Daniel M., Mielke, Kristi L., Bradford, Kandace, Bowers, Cyril Y., Miles, John M., Veldhuis, Johannes D. , Miles, John M.

The Journal of Clinical Endocrinology & Metabolism | September 7, 2004 | Volume: 89 | Issue: 9 | Pages: 4746-4754

10.1210/jc.2004-0424 Get It

Sustained Elevation of Pulsatile Growth Hormone (GH) Secretion and Insulin-Like Growth Factor I (IGF-I), IGF-Binding Protein-3 (IGFBP-3), and IGFBP-5 Concentrations during 30-Day Continuous Subcutaneous Infusion of GH-Releasing Peptide-2 in Older Men and W
Bowers, Cyril Y., Granda, Ramona, Kuipers, Jonathan, Baylink, David J. , Veldhuis, Johannes D. , Mohan, Subburaman

The Journal of Clinical Endocrinology & Metabolism | May 5, 2004 | Volume: 89 | Issue: 5 | Pages: 2290-2300

10.1210/jc.2003-031799 Get It

Estradiol Supplementation Enhances Submaximal Feed-Forward Drive of Growth Hormone (GH) Secretion by Recombinant Human GH-Releasing Hormone-1,44-Amide in a Putatively Somatostatin-Withdrawn Milieu
Veldhuis, Johannes D. , Evans, William S. , Bowers, Cyril Y.

The Journal of Clinical Endocrinology & Metabolism | November 6, 2003 | Volume: 88 | Issue: 11 | Pages: 5484-5489

10.1210/jc.2003-030410 Get It

Abstract To test the clinical hypothesis that an estrogen-enriched milieu enhances GHRH action, we administered placebo (Pl) and estradiol-17β (E2) orally for 23 d to six postmenopausal women in a prospectively randomized, double-masked, within-subject crossover design with 6 wk intervening. The GHRH stimulation protocol entailed consecutive iv infusion of l-arginine and a single iv pulse of saline or one of five randomly ordered doses of recombinant human GHRH-1,44-amide (0.03, 0.1, 0.3, 1.0, or 3.0 μg/kg) in a total of 12 separate morning, fasting sessions. GH secretion was monitored by sampling blood every 10 min for 6 h; chemiluminescence assay of GH concentrations; deconvolution analysis of stimulated GH release; and nonlinear dose-response reconstruction. Supplementation with E2, compared with Pl: 1) increased (mean ± sem) E2 concentrations from 18 ± 3 (Pl) to 164 ± 12 pg/ml (to convert to picomoles per liter, multiply by 3.57) (P < 0.001); 2) decreased IGF-I concentrations from 181 ± 14 to 120 ± 11 μg/liter (P < 0.01); 3) elevated mean GH concentrations from 0.27 ± 0.06 to 0.59 ± 0.08 μg/liter (P = 0.014); 4) potentiated GH secretion stimulated by l-arginine alone by 1.43-fold (P = 0.012); 5) reduced the ED50 of GHRH from 0.27 ± 0.02 to 0.13 ± 0.01 μg/kg (P < 0.01), denoting enhanced GHRH potency; and 6) heightened the maximal slope of the dose-response function from 1.1 ± 0.1 to 1.4 ± 0.05 [(μg/liter) (μg/kg)−1] (P < 0.05), signifying augmented pituitary sensitivity. The foregoing facilitative mechanisms were specific because E2 replacement did alter maximal l-arginine/GHRH-induced GH secretion, indicating unchanged secretagogue efficacy. In conclusion, inasmuch as E2 also attenuates inhibition of GH secretion by infused somatostatin and potentiates stimulation of GH secretion by GH-releasing peptide-2, we postulate that estrogenic steroids drive pulsatile GH production in part via mechanisms that include all three of GHRH, somatostatin, and putatively GH-releasing peptide/ghrelin signaling.